PE18095A1 - 3-bencilaminometil piperidinas sustituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines - Google Patents

3-bencilaminometil piperidinas sustituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines

Info

Publication number
PE18095A1
PE18095A1 PE1994249628A PE24962894A PE18095A1 PE 18095 A1 PE18095 A1 PE 18095A1 PE 1994249628 A PE1994249628 A PE 1994249628A PE 24962894 A PE24962894 A PE 24962894A PE 18095 A1 PE18095 A1 PE 18095A1
Authority
PE
Peru
Prior art keywords
alkyl
heteroarilsulfonamido
heteroarilamino
bencilaminometil
related compounds
Prior art date
Application number
PE1994249628A
Other languages
English (en)
Inventor
Jr Harry R Howard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE18095A1 publication Critical patent/PE18095A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE: 1) A ES UN ARILO COMO FENILO, NAFTILO, TIENILO, DIHIDROQUINOLINILO, INDOLINILO; 2) P ES NR2, O, S, SO, SO2; 3) Q ES SO2, NH, -N(ENLACE A A)-ALQUILO C1-C6, ALQUILO C1-C6-N(ENLACE A A)-SO2-; 4) W ES H, ALQUILO C1-C6, S-ALQUILO C1-C3, HALOGENO, ALCOXI C1-C6; 5) R1 ES UN ANILLO HETEROCICLICO COMO TIAZOLILO, PIRROLILO, TIENILO, TRIAZOLILO, OXAZOLILO, OXADIAZOLILO, TIADIAZOLILO, IMIDAZOLILO, LOS CUALES PUEDEN ESTAR SUSTITUIDOS; 6) R2 ES H, -CO2-ALQUILO C1-C10; 7) R3 ES UN ANILLO HETEROCICLICO QUE CONTIENE NITROGENO; EL CUAL ES ANTAGONISTA DE LA SUSTANCIA P QUE ES UN NEUROPEPTIDO
PE1994249628A 1993-09-17 1994-09-01 3-bencilaminometil piperidinas sustituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines PE18095A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12330693A 1993-09-17 1993-09-17

Publications (1)

Publication Number Publication Date
PE18095A1 true PE18095A1 (es) 1995-07-03

Family

ID=22407886

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1994249628A PE18095A1 (es) 1993-09-17 1994-09-01 3-bencilaminometil piperidinas sustituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines

Country Status (9)

Country Link
US (1) US5703065A (es)
EP (2) EP1209157A1 (es)
JP (1) JP2963200B2 (es)
AU (1) AU7082194A (es)
EC (1) ECSP941156A (es)
FI (1) FI944310A (es)
IL (1) IL110931A0 (es)
PE (1) PE18095A1 (es)
WO (1) WO1995007908A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508837A (ja) * 1994-11-10 1998-09-02 ファイザー・インコーポレーテッド 眼の疾患を治療するためのnk−1レセプターアンタゴニスト
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
DE69603615T2 (de) 1995-10-10 2000-02-17 Pfizer Nk-1 rezeptor antagonisten in neurogener entzündung in gen-therapie
WO2002022579A2 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
HUP0401154A2 (hu) * 2001-07-20 2004-10-28 Pfizer Products Inc. NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására
CA2573271C (en) 2004-07-15 2015-10-06 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ, インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
MX2009007200A (es) 2007-01-10 2009-07-15 Angeletti P Ist Richerche Bio Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
JP5319518B2 (ja) 2007-04-02 2013-10-16 Msd株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
KR20120023072A (ko) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 (S)-7-(〔1,2,4〕트리아졸〔1,5-a〕피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
EA023838B1 (ru) 2009-10-14 2016-07-29 Мерк Шарп Энд Домэ Корп. ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Erk阻害剤である新規化合物
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2891412A1 (en) 2012-11-20 2014-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲hdm2抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
CN113527418B (zh) * 2021-07-16 2022-05-03 成都普康唯新生物科技有限公司 一种ADC linker的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234946A (en) * 1987-11-27 1993-08-10 Banyu Pharmaceutical Co., Ltd. Substituted alkylamine derivatives
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
DE9290083U1 (de) * 1991-06-20 1994-02-17 Pfizer Inc., New York, N.Y. Fluoralkoxybenzylamino-Derivate von stickstoffhaltigen Heterocyclen
DE69331103T2 (de) * 1992-08-19 2002-03-14 Pfizer Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
ATE194340T1 (de) * 1992-12-10 2000-07-15 Pfizer Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
ES2087813B1 (es) * 1993-08-09 1997-02-01 Pfizer Heterociclos no-aromaticos que contienen nitrogeno bencilamino substituidos.

Also Published As

Publication number Publication date
EP0719266A1 (en) 1996-07-03
JP2963200B2 (ja) 1999-10-12
WO1995007908A1 (en) 1995-03-23
JPH08509987A (ja) 1996-10-22
AU7082194A (en) 1995-04-03
FI944310A (fi) 1995-03-18
FI944310A0 (fi) 1994-09-16
ECSP941156A (es) 1995-02-27
US5703065A (en) 1997-12-30
EP1209157A1 (en) 2002-05-29
IL110931A0 (en) 1994-11-28

Similar Documents

Publication Publication Date Title
PE18095A1 (es) 3-bencilaminometil piperidinas sustituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
PE17995A1 (es) Antagonista triciclico de vasopresina de benzacepina
ATE407924T1 (de) Stickstoffhaltige, fünfgliedrige ringverbindungen
AR014110A1 (es) Compuestos de 2-aminopiridinas, composiciones farmaceuticas, procedimiento de tratamiento, prevencion e inhibicion
CY1106534T1 (el) Αρωματικες εξαμελεις κυκλικες ενωσεις που περιεχουν αζωτο
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
PT1052254E (pt) Derivados heterocíclicos azotados e medicamento dos mesmos
EA199900591A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
ES2058809T3 (es) Derivados heterociclicos.
PE2799A1 (es) Lactamas e imidas heterociclicas de aralquilo y aralquilideno
DK0625977T3 (da) Piperazinderivater som 5-1A-antagonister
ES2108027T3 (es) Nuevos compuestos triciclicos que contienen amino y nitro, utiles como inhibidores de ace.
DK0444659T3 (da) Farmaceutisk opløsning indeholdende derivater af FK 506
ES2032229T3 (es) Inhibidores de proteasas benzamidicos.
ATE103592T1 (de) Carbamoylpyrrolidonderivate, ihre verwendung und herstellung.
AR245933A1 (es) Procedimiento para preparar compuestos de 4-(3-hidroxifenil)metil-3-alquil-n-alquilpiperidina y sus sales.
ES2177058T3 (es) Compuestos eter piperidinilaminometil trifluorometil ciclicos como antagonistas de la sustancia p.
MX9301045A (es) Procedimiento para preparar antagonistas receptores de fibrinogeno.
FI894783A0 (fi) Substituerade aromatiska foereningar med verkan pao det centrala nervsystemet.
ES2057415T3 (es) Derivados biciclicos.
CO5180536A1 (es) Inhibidores de proteasas catepsina
JPS57209231A (en) N-alkylation of nitrogen-containing organic compound
MX9302388A (es) Oxazolidinonas fungicidas y composicion fungicida que las contiene
DK0481742T3 (da) Piperazinderivater
DE69004596D1 (de) Benzodiazepin-Analoge.

Legal Events

Date Code Title Description
FD Application declared void or lapsed